Zhen Ping Zhu
Director/Board Member chez Refuge Biotechnologies, Inc.
Profil
Zhen Ping Zhu currently works at Numab Therapeutics AG, as Director from 2018 and Refuge Biotechnologies, Inc., as Director from 2018.
Dr. Zhu also formerly worked at Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., as Director & Deputy General Manager from 2019 to 2022, 3SBio, Inc., as Chief Scientific Officer & President-Research from 2017 to 2019, Kadmon Holdings, Inc., as Executive Vice President-Biologics, Kadmon Pharmaceuticals LLC, as EVP-Global Biologics Research & Development, Kadmon Corp.
LLC, as Executive Vice President-Global Biopharmaceuticals from 2010 to 2016, and ImClone Systems LLC, as Vice President.
Dr. Zhu received his doctorate degree from Dalhousie University, doctorate degree from Jiangxi Medical College, graduate degree from Chinese Academy of Medical Sciences, and graduate degree from Peking Union Medical College.
Postes actifs de Zhen Ping Zhu
| Sociétés | Poste | Début |
|---|---|---|
Refuge Biotechnologies, Inc.
 Refuge Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA. | Director/Board Member | 02/05/2018 |
Numab Therapeutics AG
 Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Director/Board Member | 01/03/2018 |
Anciens postes connus de Zhen Ping Zhu
| Sociétés | Poste | Fin |
|---|---|---|
| SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD | Chief Tech/Sci/R&D Officer | 13/01/2022 |
| 3SBIO INC. | Chief Tech/Sci/R&D Officer | 01/09/2019 |
| KADMON HOLDINGS, INC. | Corporate Officer/Principal | 06/01/2017 |
Kadmon Corp. LLC
 Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2016 |
ImClone Systems LLC
 ImClone Systems LLC BiotechnologyHealth Technology Part of Eli Lilly & Co., ImClone Systems LLC is a private company that develops and manufactures biologics for the treatment of cancer. The company is based in Bridgewater, NJ. | Corporate Officer/Principal | - |
Formation de Zhen Ping Zhu
| Dalhousie University | Doctorate Degree |
| Jiangxi Medical College | Doctorate Degree |
| Chinese Academy of Medical Sciences | Graduate Degree |
| Peking Union Medical College | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| 3SBIO INC. | Health Technology |
| SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD | Health Technology |
| Entreprise privées | 6 |
|---|---|
Kadmon Holdings, Inc.
 Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
Kadmon Pharmaceuticals LLC
 Kadmon Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Kadmon Pharmaceuticals LLC manufactures and distributes pharmaceutical products. The company is headquartered in Warrendale, PA. | Health Technology |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Health Technology |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Commercial Services |
ImClone Systems LLC
ImClone Systems LLC BiotechnologyHealth Technology Part of Eli Lilly & Co., ImClone Systems LLC is a private company that develops and manufactures biologics for the treatment of cancer. The company is based in Bridgewater, NJ. | Health Technology |
Refuge Biotechnologies, Inc.
Refuge Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Refuge Biotechnologies, Inc. develops therapeutic cells. It is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body. The firms programs include RB-1916, RB-H21 and RB-M1. The company was founded by Stanley Qi, David R. Parkinson and Bing C. Wang and is headquartered in Menlo Park, CA. | Commercial Services |
